According to a new report published by Allied Market Research, titled, "Antihyperlipidemic Drugs Market by Drug Class: Global Opportunity Analysis and Industry Forecast, 2019-2026," the global antihyperlipidemic drugs market was valued at $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.
The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-sample/6284
The rise in level of lipids in the blood is called as hyperlipidemia. The drugs that are used to treat the condition are called antihyperlipidemic drugs. Furthermore, there are major complications associated with this condition such as heart attack. Therefore, the condition requires early monitoring and treatment. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol, and others.
According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks, which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors segment is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the growth of the market include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.
The developing economies offer lucrative opportunities for antihyperlipidemic drugs providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and others. Furthermore, this report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
Key Findings of the Study:
Statins occupied one-third share of the global antihyperlipidemic drugs market in 2018.
The PCSK9 inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
The cholesterol absorption inhibitors segment accounted for more than one-fourth share of the market in 2018.
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAME
Key Market Segments
By Drug Class
Statins
Bile Acid Sequestrants
Cholesterol Absorption Inhibitors
Fibric Acid Derivatives
PCSK9 Inhibitors
Combination
Others
Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/6284
Key Market Players
ABBVIE INC.
Amgen Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
Daiichi Sankyo Company, Limited
Dr. Reddy's Laboratories Ltd
Merck & Co., Inc
Mylan N.V
Pfizer Inc.
SANOFI S.A.
